WO2026022656 - LIPID PARTICLE FORMULATIONS WITH PERMANENTLY CHARGED CATIONIC LIPIDS
National phase entry is expected:
Publication Number
WO/2026/022656
Publication Date
29.01.2026
International Application No.
PCT/IB2025/057322
International Filing Date
19.07.2025
Title **
[English]
LIPID PARTICLE FORMULATIONS WITH PERMANENTLY CHARGED CATIONIC LIPIDS
[French]
FORMULATIONS DE PARTICULES LIPIDIQUES CONTENANT DES LIPIDES CATIONIQUES CHARGÉS EN PERMANENCE
Applicants **
GENEVANT SCIENCES GMBH
Inventors
HEYES, James
LAM, Kieu
HOLLAND, Richard James
WOOD, Mark Christopher
REID, Stephen
Priority Data
63/673,913
22.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5618 | |
| EPO | Filing, Examination, Granting | 98407 | |
| Japan | Filing, Examination, Granting | 4837 | |
| South Korea | Filing, Examination, Granting | 7484 | |
| USA | Filing, Examination, Granting | 27240 |
Total:
143,586
Contact Us
Abstract[English]
The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.[French]
La présente divulgation concerne des nanoparticules lipidiques qui sont avantageusement efficaces dans le ciblage de cellules hépatiques étoilées avec une spécificité améliorée. Les nanoparticules lipidiques comprennent cinq composants lipidiques, comprenant un lipide cationique chargé en permanence qui est un lipide d'ammonium quaternaire. La divulgation concerne également des compositions pharmaceutiques et des procédés comprenant les nanoparticules lipidiques selon l’invention.